Biogen, for example, gained familiarity with such approach through its work with Ionis Pharmaceuticals, and even identified Dravet Syndrome as a good target for Ionis’ antisense tech back in ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...

It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the ...

It’s mind-blowing what used to set them off." Faith had her first seizure at five months old and was diagnosed with Dravet Syndrome at 15 months after repeated emergency hospital visits.

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are ...

Down syndrome, which causes a range of developmental differences and affects 1 in 700 newborns in the United States, is caused by the presence of an extra copy of chromosome 21. Mongkolchon ...

An estimated 20,000 to 30,000 people in the United States have Williams syndrome, which is diagnosed with genetic testing. Learn more about the center on Penn Medicine's website.

Human Interest Patient’s life-threatening stroke overlooked by doctors leads to horrific ‘locked-in’ syndrome: ‘Completely avoidable’ By Hannah Sparks Published June 19, 2025, 8:07 p.m. ET ...

According to Benzinga Pro, Biogen's peer group average for short interest as a percentage of float is 6.94%, which means the company has less short interest than most of its peers.

Biogen has commenced dosing in the Phase III BRAVE study to assess omaveloxolone in children of two to less than 16 years of age with Friedreich ataxia (FA). The trial aims to assess the safety ...

In the study, researchers found that the brains of people diagnosed with Down syndrome and Alzheimer's disease (DSAD) had twice as much iron and more signs of oxidative damage in cell membranes ...